Related Experiment Video
Updated: Jun 16, 2026

05:30
Laparoscopic Radical Gastrectomy for Remnant Gastric Cancer
Published on: October 31, 2025
The node ratio as prognostic factor after curative resection for gastric cancer
Mario Sianesi1, Lamia Bezer, Paolo Del Rio
1General and Transplantation Surgery, University Hospital of Parma, via Gramsci 14, 43100 Parma, Italy.
Summary
The node ratio (NR) is a reliable prognostic factor for gastric cancer, potentially more accurate than the TNM system. This new tool may help reduce stage migration in cancer staging.
Area of Science:
- Oncology
- Surgical Pathology
- Cancer Research
Background:
- Tumor invasion depth and nodal involvement are key prognostic factors in gastric cancer.
- Current staging systems lack standardization, necessitating new tools for result interpretation and comparison.
- The node ratio (NR) has emerged as a potential new prognostic indicator.
Purpose of the Study:
- To evaluate the prognostic value of the node ratio (NR) in gastric cancer patients.
- To compare the efficacy of NR with the TNM staging system.
- To assess the impact of the number of retrieved lymph nodes on survival outcomes.
Main Methods:
- Retrospective review of 282 gastric cancer patients undergoing curative resection (2000-2007).
- Analysis included TNM stage, NR, overall survival, and survival based on nodal status and total nodes retrieved.
- Cox regression was used to determine independent prognostic factors.
Main Results:
- Univariate analysis identified TNM stage, metastatic nodes, NR, and invasion depth as significant prognostic factors.
- Patients with >15 retrieved nodes showed significantly longer survival (p < 0.04).
- Node ratio (NR) was confirmed as an independent prognostic factor via Cox regression.
Conclusions:
- Node ratio (NR) is a sensitive and reliable tool for differentiating gastric cancer patient prognoses, potentially surpassing the TNM system.
- NR is not strongly correlated with the number of retrieved nodes, potentially mitigating stage migration.
- Further clinical trials are recommended to validate NR as a prognostic tool.
